This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Imprimis (B)
Casadesus-Masanell, Ramon; Elterman, Karen; Appel, MarcCase HBS-717496-EEntrepreneurshipThis case is a supplement to Imprimis (Case A). It describes the company's decision to enter into the pharmaceutical compounding business in 2013-14. Imprimis purchased a compounded ophthalmological medication called Dropless Therapy, which was injected into patients' eyes post-cataract surgery, with the aim of replacing a complex regimen of prescription eye drops. After a successful launch of the compounded medication, Imprimis ran into complica...Starting at €5.74
-
Money Fellows: The Quest for Expansion
RodrÃguez Arregui, Ãlvaro; Chu, Michael; Dahawy, AhmedCase HBS-324010-EEntrepreneurshipThis case explores the opportunities and challenges associated with expanding the operations of a complex entrepreneurial business model. It highlights how cultural aspects of different geographies impact a startup's operational and economic models. The case also debates the considerations of expanding operations internationally versus penetrating new customer segments within a company's existing market. Lastly, the case presents the tensions tha...Starting at €8.20
-
Embrace
Chu, Michael; Bloom, David E.; Wagonfeld, Alison BerkleyCase HBS-814001-EEntrepreneurshipStarting at €8.20
-
A Financial Perspective (Spanish version)
Segel, Arthur I; Chu, Michael; Herrero, Gustavo A.Case HBS-208S15EntrepreneurshipPatrimonio Hoy, a program targeting the housing needs of low-income families launched by CEMEX, a major Mexican corporation and a leading global cement company, has gone from a market research project to a highly visible initiative in 22 cities and has earned public recognition. The president of Cemex North America must decide whether it is corporate social responsibility or a new business line. In the process, it allows analysis of the Patrimoni...Starting at €8.20
-
Patrimonio Hoy (Spanish version)
Segel, Arthur I; Chu, Michael; Herrero, Gustavo A.Case HBS-811S14EntrepreneurshipPatrimonio Hoy es un programa dirigido a las necesidades de vivienda de la población de bajos ingresos por CEMEX, empresa mexicana importante y líder en la producción mundial de cemento. Originalmente concebido como un proyecto para comprender los clientes en el segmento de la autoconstrucción mejor, un componente principal de la casa reconocimiento de la capacidad concentrada en barrios de bajos ingresos, Patrimonio Hoy ha generado mexicana y la...Starting at €8.20
-
Imprimis (D)
Casadesus-Masanell, Ramon; Elterman, Karen; Appel, MarcCase HBS-717498-EEntrepreneurshipThis case is a supplement to Imprimis (Case A), Imprimis (Case B), and Imprimis (Case C). It describes Imprimis's 2015 decision to develop a $1 per pill compounded alternative to Daraprim, the branded drug that had recently undergone an extreme price hike, raising its price to $750/pill. Imprimis also created compounded alternatives to several other branded drugs, and made investments to increase its manufacturing capabilities. The company now ha...Starting at €5.74
-
Nubank: Democratizing Financial Services
Chu, Michael; Larangeira, Carla; Levindo, PedroCase HBS-321068-EEntrepreneurship"Nubank, a wholly-digital solution created to disrupt Brazilian banking, with 6 million clients and a $4 billion valuation after five years, must decide whether to expand to Mexico. The company was founded in S o Paulo in 2013 by Colombian-born David VStarting at €8.20
-
Imprimis (A)
Casadesus-Masanell, Ramon; Elterman, Karen; Appel, MarcCase HBS-717426-EEntrepreneurshipThis case examines the strategic choices and evolving business model of Imprimis Pharmaceuticals from the perspective of CEO Mark Baum. The A case provides a brief history of the company and of the compounding business, outlining the challenges faced by Imprimis in 2013. At the time, Imprimis was in the process of seeking FDA approval for a branded drug called Impracor. This process, already difficult, was further complicated by recent manufactur...Starting at €8.20
-
Imprimis (C)
Casadesus-Masanell, Ramon; Elterman, Karen; Appel, MarcCase HBS-717497-EEntrepreneurshipThis case is a supplement to Imprimis (Case A) and Imprimis (Case B). Set in 2015, it first describes Imprimis's decision to introduce its own line of compounded eye drop medication called LessDrops. The case then examines the moral dilemma faced by CEO Mark Baum, who was struck by the problem of high drug prices in the United States. Recent, drastic price hikes on pharmaceutical drugs, such as those initiated by Turing Pharmaceuticals under CEO ...Starting at €5.74
-
Luckin Coffee (A): Caffeine-fueled Growth
Casadesus-Masanell, Ramon; Elterman, KarenCase HBS-721370-EEntrepreneurshipThis case describes the founding of Chinese coffee chain Luckin Coffee in 2017 and its path to surpassing Starbucks as the largest coffee chain in China (by number of stores) in 2019. Unlike Starbucks stores, which were designed to be welcoming "third places" for customers to gather away from their homes or offices, most of Luckin's stores were small and bare, reflecting its mission to provide convenient takeout or delivery coffee to busy custome...Starting at €8.20